Viridian Therapeutics
VRDN
26 hedge funds and large institutions have $110M invested in Viridian Therapeutics in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 11 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
102% more capital inflows, than outflows
Capital inflows: $32.5M | Capital outflows: $16.1M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
21% less funds holding
Funds holding: 33 → 26 (-7)
49.03% less ownership
Funds ownership: 76.66% → 27.64% (-49%)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$13.6M |
| 2 |
D.E. Shaw & Co
New York
|
+$9.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.18M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$3.07M |
| 5 |
Millennium Management
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
-$9.19M |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.99M |
| 3 |
BVF Inc
San Francisco,
California
|
-$1.94M |
| 4 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.13M |
| 5 |
Driehaus Capital Management
Chicago,
Illinois
|
-$557K |
VRDN Hedge Fund Activity: Q2 2021 in Review
26 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2021, worth a combined $110M — up 30% from $84.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VRDN and 4 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 10 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $13.6M. The largest seller was Logos Global Management, exiting entirely with an estimated $9.19M sold.
- 26 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2021, down from 33 in Q1 2021.
- Funds reported $110M of Viridian Therapeutics stock for Q2 2021, up 30% quarter-over-quarter.
- 4 funds opened new Viridian Therapeutics positions in Q2 2021 and 11 closed out, a net change of -7 holders.
- The largest Viridian Therapeutics buyer in Q2 2021 was Perceptive Advisors, an estimated $13.6M added.
- The largest Viridian Therapeutics seller in Q2 2021 was Logos Global Management, an estimated $9.19M sold.
Based on aggregated 13F filings for Q2 2021.